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Abstract
Busulfan, cyclophosphamide and etoposide (BuCyE) is a commonly used conditioning regimen 
for autologous stem-cell transplantation (ASCT). This multicenter, phase 2 study examined the 
safety and efficacy of BuCyE with individually-adjusted busulfan based on pre-conditioning 
pharmacokinetics. The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL) patients 18–80 years, but was amended due to high early treatment-related 
mortality (TRM) in patients >65 years. BuCyE outcomes were compared with contemporaneous 
recipients of carmustine, etoposide, cytarabine and melphalan (BEAM) from the Center for 
International Blood and Marrow Transplant Research. Two hundred seven subjects with HL 
(n=66) or NHL (n=141) were enrolled from 32 centers in North America, and 203 underwent 
ASCT. Day 100 TRM for all subjects (n=203), patients >65 years (n=17), and patients ≤65 years 
(n=186) were 4.5%, 23.5% and 2.7%, respectively. The estimated 2-year PFS was 33% for HL, 
and 58%, 77% and 43% for diffuse large B-cell lymphoma (DLBCL; n=63), mantle cell 
lymphoma (MCL; n=29) and follicular lymphoma (FL; n=23), respectively. The estimated 2-year 
OS was 76% for HL, and 65%, 89% and 89% for DLBCL, MCL and FL, respectively. In the 
matched analysis, two-year TRM was 3.3% for BuCyE and 3.9% for BEAM, and there were no 
differences in outcomes for NHL. Patients with HL had lower 2-year PFS with BuCyE, 33% (95% 
CI: 21–46%) than BEAM, 59% (95% CI: 52–66%), with no difference in TRM or OS. BuCyE 
provided adequate disease control and safety in B-cell NHL patients ≤ 65 years, but produced 
worse PFS in HL patients when compared with BEAM.
Keywords
Non-Hodgkin lymphoma; Hodgkin lymphoma; busulfan; autologous stem cell transplantation; 
stem cell transplantation; lymphoma; chemotherapy
 INTRODUCTION
Hodgkin (HL) and non-Hodgkin lymphoma (NHL) constitute a biologically heterogeneous 
group of commonly-occurring hematological malignancies with marked variability in 
clinical behavior, treatment approaches and response to conventional therapy. Autologous 
hematopoietic stem-cell transplantation (ASCT) is a useful therapeutic modality for many 
patients with relapsed HL and relapsed or high-risk NHL. Patients with relapsed/refractory 
HL who received high-dose therapy (HDT) and ASCT as compared with conventional 
salvage chemotherapy also experienced improved outcomes.1-4 Prospective randomized 
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trials and several retrospective studies have demonstrated improved outcomes when ASCT is 
utilized for consolidation following salvage chemotherapy in patients with relapsed 
aggressive NHL.5-10 A randomized trial also showed that ASCT benefited patients with 
relapsed follicular lymphoma (FL)11, which was further supported by registry data.12 HDT 
and ASCT as initial therapy for patients with mantle cell lymphoma (MCL) and diffuse large 
B-cell lymphoma (DLBCL) with high-risk international prognostic index (IPI) remains 
controversial, but has been commonly used.13-18 At present, however, only limited data 
suggest any specific HDT regimen offers benefits over alternatives.19-24
Busulfan (Bu), an alkylating agent, has been shown to be an effective component of the 
conditioning regimen for myeloablative autologous and allogeneic hematopoietic stem cell 
transplantation.1, 4, 7, 25-29 One of the theoretical advantages of Bu-based HDT regimens 
over alternatives is that methods for monitoring plasma concentrations have been well 
established and individualized dosing is therefore possible.30 Pharmacokinetic (PK)-directed 
dose adjustment for Bu was originally developed to avoid unpredictable overexposure and 
resultant unfavorable adverse effects such as vomiting and veno-occlusive disease of the 
liver (VOD; sinusoid obstruction syndrome), especially when Bu was available only in an 
oral formulation.25, 27, 30 The introduction of intravenous (IV) Bu bypasses the problem of 
variable drug absorption from the gastrointestinal tract, which has reduced the incidence of 
adverse events (AEs). Moreover, single-institution studies showed improvement in overall 
survival (OS) for patients with NHL when oral Bu was replaced by IV Bu in HDT 
conditioning for ASCT,25, 27, 31 but multicenter data are lacking. This phase 2 trial was 
designed to examine conditioning with a PK-directed dosing regimen for IV Bu combined 
with cyclophosphamide and etoposide (BuCyE) in a multicenter setting and to compare this 
approach to conditioning with carmustine, etoposide, cytarabine and melphalan (BEAM) 
using data collected from the Center for International Blood and Marrow Transplant 
Research (CIBMTR).
 MATERIALS AND METHODS
 Study Design
This prospective, multicenter, single-arm, phase 2 study investigated the safety and efficacy 
of an IV BuCyE regimen with PK-directed Bu dosing. The primary objective was to evaluate 
the clinical outcomes including progression-free survival (PFS; primary endpoint), overall 
survival (OS), transplant-related mortality (TRM) and overall response rate. TRM was 
defined as a death after transplant due to any cause other than disease progression. Toxicity 
was defined by the National Cancer Institute Common Terminology Criteria for Adverse 
Events, Version 3. The secondary objective was to compare the clinical outcomes of subjects 
receiving the BuCyE regimen with those receiving a conditioning regimen with BEAM from 
centers not participating in this clinical trial, as obtained from CIBMTR registry 
data.5, 6, 12, 32 CIBMTR data management procedures have been described previously.33 In 
addition, the accuracy of PK-directed BU dose adjustment utilizing the test-dose method 
was evaluated.
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 Study Eligibility
Eligible subjects were those who required first ASCT for HL and B-cell NHL. All subjects 
had relapsed disease after initial therapy or were initially refractory to an anthracycline-
based chemotherapy and had achieved complete remission (CR) or partial remission (PR) 
following salvage chemotherapy according to the Cheson criteria.34 Additionally, subjects 
with NHL with IPI35 score 4–5, or MCL were eligible for study treatment as a part of 
primary therapy. All subjects were required to have had an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0–2, with at least 2 × 106 CD34+ cells/kg previously 
stored. Patients with major organ dysfunction or prior treatment with Bu or gemtuzumab 
ozogamicin were excluded. The study initially enrolled subjects of 18–80 years, but the 
protocol was amended to reduce the upper age limit to 65 years due to a high TRM rate at 
100 days post-transplant for subjects aged >65 years. All subjects provided written informed 
consent in accordance with the Declaration of Helsinki principles to participate in this study. 
The trial was registered at www.clinicaltrials.gov as NCT00948090. The same eligibility 
criteria were applied to the comparator group, selecting patients aged 18–65 years who had 
received ASCT with BEAM conditioning from 2008 to 2010 in US and Canadian transplant 
centers not participating in the above mentioned clinical trial and who were registered with 
CIBMTR.
 PK-Directed Dose Adjustment of Busulfan
The method of adjusting busulfan dose per patient via individual PK parameters has been 
reported previously.36 In brief, six serial blood samples were collected in sodium heparin 
tubes after administration of the IV Bu test dose (initial therapeutic drug monitoring [TDM]) 
and the first individualized conditioning dose on day −8 (confirmatory TDM). For the initial 
TDM, a test dose of IV BU (0.8 mg/kg) was administered over 2 hours between days −14 
and −11. This dose was intended to achieve an area-under-the-curve (AUC) of 1000–1500 
μM•min. Blood samples were collected at the end of the 2-hour infusion and 15, 30, 120, 
180 and 240 minutes thereafter. For the confirmatory TDM on day −8, individual IV Bu 
doses were calculated to achieve a total AUC of 20,000 μM•min, including the AUC from 
the test and confirmatory doses.4, 30 Samples for confirmatory TDM were collected at the 
end of the 3-hour infusion and 30, 90, 180 and 300 minutes thereafter.
The first sample for both the test dose and confirmatory TDM were drawn at the end of the 
infusion and no samples were drawn during the infusion. Samples were stored on wet-ice or 
refrigerated immediately after collection, centrifuged at 4°C, and stored at −20°C or below 
until shipping. To allow same day sample shipping and expedite availability of PK results, 
test dose and confirmatory TDM sampling were limited to 240 and 300 minutes after the end 
of infusion, respectively. Standard sampling timepoints were utilized for the test dose, based 
on 0.8 mg/kg every 6 hours sampling schedule.37-39 For the confirmatory TDM sampling, 
Bu clearance and AUC estimates have been shown to be comparable from PK sampling over 
8 (300 minutes after the end of infusion),11, and 24 hours after the start of infusion for every 
24 hour administration and, thus, sampling was limited to 300 minutes after the end of 
infusion. 40
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The pharmacokinetics laboratory at the Seattle Cancer Care Alliance (SCCA) measured 
plasma Bu concentrations and recommended individualized Bu dosing. Concentrations were 
analyzed by gas chromatography with mass selective detection as previously described.41 
The dynamic range was from 62 to 4500 ng/mL and the intraday and interday coefficient of 
variations were less than 5% and 8%, respectively. Bu AUC from time 0 to infinity and its 
estimated corresponding clearance were determined using a one-compartment first-order 
elimination model via WinNonlin® version 5.2 (Pharsight, Sunnyvale, CA, USA).38, 40 
Targeted daily AUC during the conditioning regimen was calculated as follows:
Targeted daily conditioning AUC (μM•min) = [20,000 (μM•min) – test dose measured AUC 
(μM•min)] / 4
The conditioning regimen daily busulfan dose was then calculated as follows:
Bu IV daily conditioning dose (mg) = Test dose (mg) × targeted daily conditioning AUC 
(μM•min) / test dose measured AUC (μM•min)
Accuracy of the test dose prediction was assessed by the percent error calculation:
[(Predicted AUCday-8 by the test dose – Confirmed AUCday-8)/Confirmed AUCday-8] × 100
Accuracy of the dose adjustment was assessed by the percent error calculation:
[(Confirmed AUCday-8 – Target AUCday-8)/Target AUCday-8] × 100
 Conditioning Regimen With BuCyE
The conditioning regimen consisted of PK-directed doses of Bu on days −8 through −5 (see 
previous section), etoposide 1.4 g/m2 on day −4 and cyclophosphamide 2.5 g/m2 on days −3 
and −2, followed by stem-cell infusion on day 0. Individualized doses of IV Bu were 
administered over 3 hours once daily. IV Bu doses on days −6 and −5 were modified only 
when the second PK results on day −8 indicated further adjustment were required to achieve 
Bu exposure of 20,000 μM•min (± 20%; cumulative Bu exposure between 16,000 to 24,000 
μM•min). Although no seizure prophylaxis was instituted during the test dose of IV Bu 
administration, benzodiazepines and/or levetiracetam were used as anti-seizure medications 
for conditioning. Peritransplant palifermin and post-transplant use of colony-stimulating 
factor use were not restricted.
 Statistical Analysis
The endpoints of PFS and OS were depicted graphically by Kaplan-Meier curves. Median 
survival in months, with 95% confidence intervals, as well as one- and two-year survival 
rates were also estimated. Disease responses were summarized by frequency and percentage 
at each of the specified time points. Efficacy analyses were based on the modified ITT data 
set.
This study had a pre-specified endpoint (as described in the approved clinical protocol) 
comparing efficacy of BuCyE with BEAM from CIBMTR registry data. Baseline 
characteristics of patients enrolled in this clinical trial 65 years of age or younger were used 
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to match with CIBMTR controls. All patients from the phase 2 study selected for efficacy 
analyses were matched with up to four patients treated with BEAM obtained from CIBMTR 
to provide approximately 80% power to demonstrate 11% difference in the 2-year PFS rate, 
assuming that the 2-year PFS rates for BuCyE and BEAM were 66% and 55%, 
respectively.24, 42 The four criteria used for matching were: age ± 10 years, Karnofsky 
Performance Score (≥ 90%, < 90%), disease status prior to transplant as defined above 
(CR1, CR2 or higher, PR) and histology (HL, FL, DLBCL, MCL, Burkitt, and others). All 
patients were followed-up for at least 1 year until May 2013, which provided an 
approximate median 2-year follow-up for this study. Follow-up visits were timed to match 
the CIBMTR registry follow-up time points for data comparability: day 100, 6 months, 1 
year, and every year after 1 year.
Baseline characteristics at transplantation were tabulated and compared for the phase 2 
BuCyE group and the matched CIBMTR cohort conditioned with BEAM. Outcomes were 
tabulated for patients in the phase 2 BuCyE trial and compared with the matched BEAM 
patients from the CIBMTR. Survival curves were constructed using the Kaplan-Meier 
method and were compared by a two-sided log-rank test. Multivariable Cox regression 
analyses were conducted to compare clinical outcomes after HCT between BuCyE and 
BEAM. To account for the intra-cluster correlation resulting from covariates matching, 
marginal models approach were used in all comparisons. Marginal Cox models43 were used 
to evaluate prognostic factors for PFS, TRM and OS. The proportional hazards assumption 
was met. An interaction test indicated a differential effect of conditioning regimen by 
disease type on PFS; therefore, the comparisons are presented by disease type. A level of 
significance (α) of 0.05 was defined as statistically significant. All statistics were computed 
using SAS 9.3.
 RESULTS
 Patient Disposition and Demographics
A total of 207 subjects with HL (n=66) or NHL (n=141) were enrolled from 32 centers in 
the US and Canada between February 2010 and April 2012. Four subjects did not proceed 
with ASCT due to insurance or eligibility issues. One patient who experienced a syncopal 
episode after etoposide administration was not treated with cyclophosphamide and 
discontinued from the study on day −1. This patient was included in the intent-to-treat 
population, as stem cells were infused as planned. In addition, four patients were identified 
as ineligible, but were included in the intent-to-treat analyses. These included: T-cell 
lymphoma (n=1), failure to confirm CR or PR (n=1), history of hepatitis C (n=1), and a 
patient with FL who did not receive prior anthracycline (n=1). The study initially enrolled 
subjects of 18–80 years, but the protocol was amended to reduce the upper age limit to 65 
years due to a high TRM rate at 100 days post-transplant for subjects >65 years. We report 
safety for all the subjects undergoing ASCT (n=203) and efficacy from those aged ≤ 65 
years (n=186), and recipients of BuCyE who were matched to up to a maximum of 4 BEAM 
patients yielding a total of 729 controls.
At baseline, 67% of subjects were male, 87% were Caucasian and 6% were African 
American, and 96% had an ECOG performance status of 0–1 (Table 1). Median time from 
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initial diagnosis to the autologous transplant was 18.4 months (range: 71 days to 262 
months). Lymphoma subtypes and disease status at transplantation are described in Table 1.
 PK-Directed Dose Adjustment of Busulfan
Of the 203 subjects undergoing ASCT in the present study, 200 subjects used individualized 
Bu doses determined by initial TDM, whereas three subjects used 3.2 mg/kg on days −8 and 
−7 due to non-evaluable test PK results. Confirmatory TDM samples were collected from 
203 subjects on day −8 (n=201) or day −7 (n=2). In one subject, confirmatory TDM was 
equivocal and not utilized. Consequently, 199 subjects had two sets of evaluable PK 
parameters obtained with initial and confirmatory TDM.
Among the 199 subjects, median Bu clearance calculated from initial TDM was 2.98 
ml/min/kg (range 1.95–4.39 ml/min/kg). Overall, 2.9% of subjects had an AUC of >1,500 
μM•min and 32.8% of subjects had an AUC of <1,000 μM•min (Figure 1). In total, 35.8% of 
subjects would likely have been outside the AUC target range if weight-based dosing had 
been used without TDM. A greater proportion of obese (BMI ≥30) or overweight (BMI = 
25.0–29.9) subjects were underexposed to Bu compared with those with normal BMI (BMI 
= 18.5–24.9) (Table 2). However, stratification by BMI was not sufficient to identify any 
specific patient population that would not have required TDM. After PK-directed dose 
adjustments, 95.0% of subjects fell within the target range for total AUC after PK-directed 
dose adjustments based on initial and confirmatory PK (AUC = 20,000 μM•min ± 20%, 
Figure 2); 3.0% and 2.0% subjects required additional dose reductions and increases for the 
last 2 days respectively. Mean absolute error for the test dose predicted AUCday-8 
(confirmatory PK) was 7.4% (95% CI 6.5 to 8.3%). Evaluating the accuracy of test PK-
based dose adjustments based on the margin of error from the desired daily target exposure, 
mean absolute error was 7.5% (95% CI 6.5 to 8.4%). No significant change in clearance was 
observed between test PK and confirmatory PK (p=0.220, paired t-test), indicating that intra-
patient variability in clearance was minimal. Median total IV Bu administered was 14.5 
mg/kg of actual body weight (range: 8.8–20.1 mg/kg). Busulfan exposure was similar to the 
overall population in the subgroup of patients experiencing the AEs of TRM or mucositis 
(Figure 3).
 Adverse Events
An early subset-analysis by age in June 2011 revealed that four of 17 subjects >65 years 
suffered TRM by day 100 which met a protocol-specified stopping rule for this population. 
The TRM rates by day 100 for all subjects (n=203), patients >65 years (n=17), and patients 
≤65 years (n=186) were 4.5% (95% confidence intervals [CI)]: 2.1–8.3%), 23.5% (95% CI: 
6.8–49.9%) and 2.7% (95% CI: 0.9–6.2%), respectively. The most common AEs leading to 
death were respiratory failure (4 subjects, 1.9%), sepsis (3 subjects, 1.4%), multi-organ 
failure (2 subjects, 1.0%), and acute respiratory distress syndrome (2 subjects, 1.0%). 
Serious AEs with an incidence of 2% or greater were recorded for 90 (43.5%) subjects. The 
most common grade 3/4 AEs observed in subjects ≤65 years were febrile neutropenia 
(Grade 3: 54%; 4: 3%), stomatitis (Grade 3: 41%; 4: 0%), nausea (Grade 3: 10%; 4: 0%), 
and pneumonia (Grade 3: 7% ; 4:0%). There were no instances of seizure or hepatic VOD 
based on Baltimore criteria.44 Other grade ≥3 AEs are listed in Table 3.
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 Efficacy of BuCyE
Efficacy was analyzed for 186 subjects ≤65 years old with HL (n=65) or NHL (n=121), 
including: DLBCL (n=63), MCL (n=29) and FL (n=23). Of the 186 patients, 156 (84%) 
underwent transplant in PR or CR2 or higher. The remainder (n=30) underwent ASCT in 
CR1/CRu1, including 19 patients with MCL. With median follow-up of 20 months, the 
estimated 2-year PFS was 33% for HL and 58%, 77% and 43% for DLBCL, MCL and FL, 
respectively. The estimated 2-year OS was 76% for HL and 65%, 89% and 89% for DLBCL, 
MCL and FL, respectively. The OS and PFS curves for the phase 2 study of PK-directed 
BuCyE are shown in Figures 4 and 5, respectively.
 Comparisons of BuCyE with Matched CIBMTR Patients
Of the 186 patients, 183 recipients of BuCyE with lymphoma in complete or partial response 
were matched at a maximum ratio of 4:1 with 729 CIBMTR controls based on age, 
performance status, disease status prior to transplant and lymphoma histology. No matches 
were found for three patients. In total, 177 cases had 4 matched controls, and 97% of 
controls had an age difference from controls of ≤ 5 years. A comparison of patients from the 
phase 2 trial of BuCyE and the matched cohort of patients conditioned with BEAM from the 
CIBMTR is shown in Table 4. Patients were well-matched for age, performance status, 
histologic subtype and response prior to transplant, and the median follow up was 22 months 
in both cohorts.
Two-year cumulative incidences of TRM were 3.3% (95% CI: 1.4–6.6%) and 3.9% (95% 
CI: 2.4–5.7%) for BuCyE and BEAM, respectively. Corresponding 2-year probabilities of 
OS were 76% (95% CI: 68–82%) and 78% (95% CI: 74–82%). Tables 5 and 6 compare 
outcomes for NHL and HL separately. Multivariate analysis demonstrated a significant 
interaction between disease and conditioning regimen in evaluation of disease progression 
and treatment failure. Analyses by histology demonstrated that among patients with NHL, 
there were no differences in outcomes between groups. Among patients with HL treated 
with BuCyE or BEAM, respectively, the 2-year cumulative incidence of progression was 
66% (95% CI: 53–77%) and 38% (95% CI: 31–45%) and 2-year PFS was 33% (95% CI: 
21–46%) and 59% (95% CI: 52–66%), with no difference in TRM or OS. The 2-year 
cumulative incidences of TRM were 3.3% (95% CI: 1.4–6.6%) and 3.9% (95% CI: 2.4–
5.7%) for BuCyE and BEAM, respectively. Survival curves comparing BuCyE and BEAM 
conditioning from this matched analysis for NHL and HL are shown in Figures 6 and 7.
 DISCUSSION
This was the first large-scale, multicenter, prospective study in North America in which the 
IV weight-based Bu dose was further adjusted based on PK results from a pre-conditioning 
test dose. We found that simple pre-conditioning TDM accurately estimated Bu clearance, 
allowing for adequate conditioning dosing. Accuracy of the test dose prediction and 
accuracy of test dose-based dose adjustments were high, comparable to previous studies in 
which clearance remained consistent across a preconditioning test PK and a conditioning 
regimen for oral and IV Bu.45-47 Although infusion rates differed between the test dose and 
the first therapeutic dose by approximately 2- to 4-fold, infusion rate-dependent nonlinear 
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behavior was not noted. This may be due to determination of Bu AUC and its estimated 
corresponding clearance using a one-compartment model versus noncompartmental analysis. 
Bu AUC estimates appear to more variable using noncompartmental analysis.40 In addition, 
a population PK analysis demonstrated that Bu PK can be adequately described by a linear 
PK model without inter-occasional variability.48 In this study, more than one-third of 
patients would have had suboptimal exposure to IV Bu if weight-based dosing alone had 
been used for conditioning, whereas 95% of subjects achieved the target range of Bu 
exposure after the introduction of individualized TDM. A pre-conditioning test dose may be 
more convenient for transplant centers relying on external PK laboratories and can offer 
another opportunity for TDM on the first day of conditioning if the initial PK results are not 
evaluable.
Results from the present study further showed that such PK-directed Bu doses in 
combination with cyclophosphamide and etoposide constituted a tolerable regimen for 
lymphoma patients <65 years of age and was associated with expected transplant 
conditioning toxicities and a TRM <5%. BuCyE was not well tolerated in patients ≥65 
years, resulting in unacceptable early TRM for older patients with lymphoma. For patients 
with NHL, PK-directed IV BuCyE produced similar PFS and OS to contemporary patients 
treated with BEAM; however, a statistically significant difference in PFS was observed 
between BuCyE and BEAM in subjects with HL, indicating superior outcomes for BEAM in 
terms of relapse and PFS. Although this trial and the additional matched cohort study design 
were not originally powered to test the difference between the BuCyE and BEAM arms for 
subjects with HL, the sample size for the phase 2 cohort subset and the 4:1 matching 
approach were reasonably large for examining this comparison and strength of the 
association warrants notice.
Previous clinical data using Bu and cyclophosphamide with or without etoposide have 
yielded clinical results that are comparable to the other preparative regimens for ASCT in 
both NHL and HL.4, 7, 24, 26, 27, 29, 30 Bu exposure (as assessed by AUC) has been associated 
with differences in survival and AEs. Kebriaei and colleagues showed that an optimally-
dosed group had a significantly better survival rate than those with lower or higher 
exposures. Fixed-dose IV Bu administration resulted in two thirds of all the subjects 
achieving AUC values within the optimal window, but PK-directed dosing increased the 
frequency of patients within the targeted range of AUC exposure up to 95%. The 2-year OS 
and PFS were 85% and 57%, respectively, for patients with HL, and 67% and 64%, 
respectively, for patients with NHL.49 While the outcomes associated with BuCyE for NHL 
appear similar to BEAM in the present matched analysis, this is not the case for HL.
One common concern of Bu-based conditioning for patients with HL has been the 
possibility of overlapping toxicity with prior HL therapies such as bleomycin, prior 
alkylating agents and radiation. However, our findings do not suggest poor outcomes from 
BuCyE due to excess toxicity or TRM. Indeed, day-28 and day-100 TRM rates were 0% and 
1.6%, respectively, for HL patients who received BuCyE conditioning. The primary 
differences observed between BuCyE and BEAM in this analysis of HL patients was an 
increase in early relapses, suggesting that BuCyE may be an inferior regimen for disease 
control among patients with relapsed HL. Why this regimen would produce worse PFS in 
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HL but not in NHL or any NHL subtype remains unclear. A prior single institution study of 
72 patients with HL or NHL conditioned with either cyclophosphamide, etoposide, 
carmustine (CEB) or BEAM found a higher prevalence diarrhea in the BEAM group (81 vs. 
51%, P = .0026), but higher OS with BEAM than with CEB (84 vs. 60%); however, 
outcomes were not stratified by lymphoma subtype.50 Chen et al. compared outcomes after 
ASCT across different conditioning regimens and among patients with HL, and busulfan-
based regimens were also associated with inferior outcomes.51
Interpretation of our findings should also consider the limitations of a non-randomized 
comparison between the cases and controls. Despite constructing a matched cohort of 
CIBMTR patients for comparison, unmeasured but important factors could be unbalanced 
between the two groups, which could bias the interventions. Nevertheless, the matching 
strategy effectively identified a large, contemporary cohort of patients who were similar in 
age, performance status and lymphoma subtype, which were previously identified as 
important determinants of outcome. Additionally, the control cohort patients were from 
centers not participating in the clinical trial, which minimized selection bias.
At present, identifying the preferred therapy for relapsed HL remains complex, and the most 
effective form of HDT may differ by patient characteristics. Nevertheless, given the dearth 
of randomized controlled trials to inform the management of patients with relapsed HL 
undergoing ASCT, careful consideration of these findings should be undertaken and BEAM 
conditioning should be preferred for patients with HL undergoing ASCT when all other 
factors are equivalent.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Phase 2 study of B-cell NHL and HL examined the safety and efficacy of BuCyE
Individually-adjusted busulfan based on pre-conditioning PK
BuCyE outcomes compared with contemporaneous recipients of BEAM registry data
BuCyE provided adequate disease control and safety in B-cell NHL patients ≤ 65 years
BuCyE produced worse PFS in HL patients when compared with BEAM
Flowers et al. Page 15
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Measured AUC from 0.8 mg/kg of IV Bu as a pre-conditioning test PK on one of the 
days, day −14 to day −11 (n=204)
Dotted line represents ± 20% range of the target AUC (1000–1500 μM●min).
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Figure 2. Histograms of estimated total AUC from test PK and confirmatory PK results (n=199)
Dotted line represents the ± 20% range of the target AUC (16,000–24,000 μM●min).
Flowers et al. Page 17
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Scatter plot of total estimated Bu area under the curve for all patients and of actual Bu 
area under the curve for patients with adverse events of transplant-related mortality (TRM) and 
mucositis/stomatitis (M/S)
Scatter plots represent subjects with no M/S and Grades (GR) 1, 2, and 3 M/S. There were 
no cases of GR 4 M/S.
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Figure 4. Overall survival for the phase 2 study of pharmacokinetics-directed busulfan, 
cyclophosphamide and etoposide conditioning and autologous stem cell transplantation for 
lymphoma
A) HL/NHL. B) NHL subtypes.
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Figure 5. Progression-free survival for the phase 2 study of pharmacokinetics-directed busulfan, 
cyclophosphamide and etoposide conditioning and autologous stem cell transplantation for 
lymphoma
A) HL/NHL. B) NHL subtypes.
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Figure 6. Comparison of survival for NHL patients in the matched analysis of phase 2 BuCyE 
and contemporary lymphoma patients treated with BEAM from CIBMTR
A) Overall survival. B) Progression-free survival.
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Figure 7. Comparison of survival for HL patients in the matched analysis of phase 2 BuCyE and 
contemporary lymphoma patients treated with BEAM from CIBMTR
A) Overall survival. B) Progression-free survival.
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Table 1
Patient Demographics.
Total patients, n 203
Age, median (range) 51 (19–72)
Male, n (%) 139 (67)
Race, n (%)
    Caucasian 177 (87%)
    African American 13 (6%)
    American Indian or Alaskan Native 2 (1%)
    Asian 7 (3%)
    Other 4 (2%)
ECOG performance status, n (%)
    0 85 (42%)
    1 109 (54%)
    2 7 (3%)
    Missing 2 (1%)
Body weight, median kg (range) 83.4 (38.8–178.2)
Body mass index, mean kg/m2 (SD) 29.2 (6.3)
Classifications, n (%)
    Hodgkin's lymphoma 66 (32)
    Non-Hodgkin's lymphoma 137 (68)
    Diffuse large B-cell 74 (54%)
    Follicular 25 (18%)
    Mantle cell 32 (23%)
    Others 6 (4%)
Status at transplantation in ITT group, n (%)
    1st CR 55 (27)
    2nd CR 66 (32)
    3rd CR or higher 5 (2)
    Primary induction failure/in relapse 6 (3)
    Partial remission 71 (35)
    Without prior CR 46 (22)
    With prior CR 20 (10)
ASCT, autologous stem-cell transplantation; CR, complete remission; ECOG, Eastern Cooperative Oncology Group; ITT, intent-to-treat 
population.
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Table 2
Area Under the Curve Exposure From Test Dose (0.8 mg/kg of Intravenous Busulfan) by Body Mass Index 
Category
BMI Category (kg/m2) BMI (kg/m
2) 
(Mean ± SD)
Clearance (mL/
minute/kg) Median 
(range)
AUC (n)
Total (n)< 1000 μM•min < 1000 to 1500 
μM•min
> 1000 μM•min
Underweight (< 18.5) 17.9 ± 0.51 2.76 (2.50 to 2.30) 0 4 (100%) 0 4
Normal (18.5 to 24.5) 22.9 ± 1.63 2.85 (1.95 to 4.39) 10 (18.5%) 40 (74.0%) 4 (7.4%) 54
Overweight (25.0 to 29.9) 27.6 ± 1.48 2.92 (2.15 to 4.11) 23 (33.8%) 42 (62.7%) 2 (3.0) 67
Obese (30.0) 35.4 ± 5.10 3.16 (2.43 to 4.20) 34 (43.0) 45 (56.9%) 0 79
AUC, area under the concentration–time curve; BMI, body mass index; Bu, busulfan; IV, intravenous; SD, standard deviation.
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Table 3
Grade 3/4 Adverse Events Following Pharmacokinetics-Directed Busulfan, Cyclophosphamide and Etoposide 
Conditioning. N = 203.
Grade 3 n (%) Grade 4 n (%) Total of Grade ≥3 n (%)
Febrile neutropenia 110 (54) 7 (3) 117 (57)
Stomatitis 84 (41) 0 84 (41)
Nausea 21 (10) 0 21 (10)
Hypophosphatemia 14 (7) 2 (1) 16 (8)
Pharyngeal inflammation (esophagitis) 10 (5) 0 10 (5)
Pneumonia 15 (7) 0 15 (7)
Hypokalemia 12 (6) 1 (0.5) 13 (6)
Diarrhea 12 (6) 0 12 (6)
Decreased appetite 13 (6) 0 13 (6)
Hypoxia 11 (5.3) 1 (0.5) 12 (6)
Hepatic veno-occlusive disease (Baltimore criteria) 0 0 0
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Table 4
Characteristics of Patients Aged ≤ 65 Years in the Matched Analysis of Phase 2 BuCyE and Contemporary 
Lymphoma Patients Treated with BEAM From CIBMTR.
BuCyE BEAM
Number of patients, n 183 729
Age at transplant, median years (range) 52 (19–65) 50 (19–65)
Age group at transplant, n (%)
    18–20 years 1 (< 1) 10 (1)
    20–30 years 23 (11) 102 (13)
    30–40 years 29 (16) 99 (14)
    40–50 years 38 (21) 153 (21)
    50–60 years 59 (32) 229 (32)
    60–65 years 33 (18) 132 (18)
Karnofsky score, n (%)
    < 90% 42 (23) 167 (23)
    ≥ 90% 139 (76) 552 (76)
    Missing 2 (1) 6 (1)
Histology, n (%)
    NHL
        Follicular 23 (13) 90 (12)
        DLBCL 62 (34) 246 (34)
        Mantle cell 29 (16) 112 (15)
        Other 5 (2) 21 (3)
    HL
        Lymphocyte predominant 2 (1) 1 (< 1)
        Nodular sclerosis 46 (24) 212 (29)
        Mixed cellularity 7 (4) 13 (2)
        Lymphocyte depleted 0 2 (< 1)
        Nodular lymphocyte predominant 2 (1) 11 (1)
        Unclassified not further specified 7 (4) 17 (2)
BEAM, carmustine, etoposide, cytarabine and melphalan; BuCyE, IV busulfan, cyclophosphamide and etoposide; CIBMTR, Center for 
International Blood and Marrow Transplant Research; DLBCL, Diffuse large B-cell lymphoma; HL, Hodgkin's lymphoma; NHL, Non-Hodgkin's 
lymphoma.
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Table 5
Comparison of Outcomes for NHL Patients in the Matched Analysis of Phase 2 BuCyE and Contemporary 
Lymphoma Patients Treated with BEAM From CIBMTR.
BuCyE (Estimate n [95% CI]) BEAM (Estimate n [95% CI]) P-value
Treatment-related mortality
    N 119 466
    At 1 year 4 (1–9) 3 (2–5) 0.626
    At 2 years 4 (1–9) 4 (2–7) 0.924
Relapse/progression
    N 119 466
    At 1 year 26 (19–35) 27 (23–32) 0.847
    At 2 years 36 (27–46) 41 (35–46) 0.410
Progression-free survival
    N 119 466
    At 1 year 69 (61–77) 70 (65–74) 0.984
    At 2 years 60 (50–69) 55 (49–60) 0.398
Overall survival
    N 119 468
    At 1 year 83 (76–89) 84 (80–87) 0.839
    At 2 years 76 (67–84) 75 (70–79) 0.816
BEAM, carmustine, etoposide, cytarabine and melphalan; BuCyE, IV busulfan, cyclophosphamide and etoposide, CI, confidence interval; 
CIBMTR, Center for International Blood and Marrow Transplant Research; NHL, non-Hodgkin's lymphoma.
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Table 6
Comparison of Outcomes for HL Patients in the Matched Analysis of Phase 2 BuCyE and Contemporary 
Lymphoma Patients Treated with BEAM from CIBMTR.
BuCyE (Estimate n [95% CI]) BEAM (Estimate n [95% CI]) P-value
Treatment-related mortality
    N 64 253
    At 1 year 2 (0–6) 2 (1–4) 0.805
    At 2 years 2 (0–6) 3 (1–6) 0.514
Relapse/progression
    N 64 253
    At 1 year 55 (43–67) 30 (24–36) < 0.001
    At 2 years 66 (53–77) 38 (31–45) < 0.001
Progression-free survival
    N 64 253
    At 1 year 43 (31–55) 68 (62–74) < 0.001
    At 2 years 33 (21–46) 59 (52–66) < 0.001
Overall survival
    N 64 255
    At 1 year 90 (82–96) 95 (92–98) 0.241
    At 2 years 76 (64–87) 85 (79–91) 0.168
BEAM, carmustine, etoposide, cytarabine and melphalan; BuCyE, IV busulfan, cyclophosphamide and etoposide, CI, confidence interval; 
CIBMTR, Center for International Blood and Marrow Transplant Research; HL, Hodgkin's lymphoma.
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